| abstract |
(57) [Summary]nImproved methods of treating immune cell mediated systemic diseases, particularly T and B cell mediated diseases, are provided by increasing the systemic exposure, or bioavailability, of the therapeutic protein. Such therapeutic proteins are selected from the group consisting of monoclonal antibodies, soluble receptors, and soluble ligands that bind to antigens expressed on the surface of immune cells. |